Stocks making the biggest moves midday: Bristol-Myers Squibb, Twitter, Gilead Sciences and more

cnbc.com:

In this article

Check out the companies making the biggest moves midday Monday:

Gilead Sciences — Shares of Gilead rose 3.8% after the biopharmaceutical company revealed it settled a patent case over its HIV therapies with five generic drugmakers.

Twitter — Shares of Twitter slipped 2% after the company said in a regulatory filing that Elon Musk's latest attempt to cancel the deal to buy the social media group is invalid. Most recently, Musk attempted to terminate the purchase citing Twitter's treatment of a whistleblower.

Carvana — Carvana surged 7.8% after it was upgraded to overweight from neutral by Piper Sandler. Analyst Alexander Potter called the stock «grossly undervalued» and believes Carvana could double from current levels.

Newmont — The gold mining company gained 2.6% after Goldman Sachs initiated coverage of the stock with a buy rating. Analyst Emily Chieng said Newmont looks undervalued after falling 30% and pointed to the company's new development projects in the pipeline that can boost growth.

Bristol-Myers Squibb — Shares of the biopharmaceutical company popped 5.4% after the U.S. Food and Drug Administration approved Bristol-Myers' oral treatment for plaque psoriasis known as Sotyktu.

Amgen — Amgen shares fell 3.7% after the approval of Bristol-Myer Squibb's psoriasis drug, which will compete with Amgen's Otezla. Separately, the biotech company reported over the weekend that its Lumakras pill reduced the risk of lung cancer progression by 34% compared with chemotherapy in a clinical trial,

Alphatec — Shares jumped 7.7% after Morgan Stanley initiated coverage of the medical technology company with an overweight rating. According to the firm, Alphatec outpaces peers and has «significant runway» head for